Centus Gets European Bevacizumab Approval

Equidacent Rival To Avastin Gains Marketing Authorization

 
• By Dave Wallace

Centus Biotherapeutics has received formal European Commission approval for its Equidacent biosimilar rival to Avastin.

Thumbs_Up_EU
Centus has received formal European Commission approval for bevacizumab • Source: Shutterstock

More from Biosimilars

More from Products